Proteasome inhibitors reduce luciferase and β-galactosidase activity in tissue culture cells

被引:41
作者
Deroo, BJ [1 ]
Archer, TK [1 ]
机构
[1] NIEHS, Reprod & Dev Toxicol Lab, Chromatin & Gene Express Sect, NIH, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1074/jbc.C200173200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Reporter enzymes are commonly used in cell biology to study transcriptional activity of genes. Recently, reporter enzymes in combination with compounds that inhibit proteasome function have been used to study the effect of blocking transcription factor degradation on gene activation. While investigating the effect of proteasome inhibition on steroid receptor activation of the mouse mammary tumor virus (MMTV) promoter, we found that treatment with proteasome inhibitors enhanced glucocorticoid activation of the promoter attached to a chloramphenicol acetyltransferase (CAT) reporter, but inhibited activation of MMTV attached to a firefly luciferase or beta-galactosidase reporter. MMTV RNA levels under these conditions correlated with the promoter activity observed using the CAT reporter, suggesting that proteasome inhibitor treatment interfered with luciferase or beta-galactosidase reporter assays. Washout experiments demonstrated that the majority of luciferase activity was lost if the proteasome inhibitor was added at the same time luciferase was produced, not once the functional protein was made, suggesting that proteasome inhibition interferes with production of luciferase protein. Indeed, we found that proteasome inhibitor treatment dramatically reduced the levels of luciferase and beta-galactosidase protein produced, as determined by Western blot. Thus, treatment with proteasome inhibitors interferes with luciferase and beta-galactosidase reporter assays, possibly by inhibiting production of a functional reporter protein.
引用
收藏
页码:20120 / 20123
页数:4
相关论文
共 29 条
[11]  
Lee PH, 1998, INT J ROBUST NONLIN, V8, P39, DOI 10.1002/(SICI)1099-1239(199801)8:1<39::AID-RNC285>3.0.CO
[12]  
2-P
[13]   The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation [J].
Lonard, DM ;
Nawaz, Z ;
Smith, CL ;
O'Malley, BW .
MOLECULAR CELL, 2000, 5 (06) :939-948
[14]   Diversity in translational regulation [J].
Macdonald, P .
CURRENT OPINION IN CELL BIOLOGY, 2001, 13 (03) :326-331
[15]   THERMOSTABILITY OF A NUCLEAR-TARGETED LUCIFERASE EXPRESSED IN MAMMALIAN-CELLS - DESTABILIZING INFLUENCE OF THE INTRANUCLEAR MICROENVIRONMENT [J].
MICHELS, AA ;
NGUYEN, VT ;
KONINGS, AW ;
KAMPINGA, HH ;
BENSAUDE, O .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 234 (02) :382-389
[16]   Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo [J].
Molinari, E ;
Gilman, M ;
Natesan, S .
EMBO JOURNAL, 1999, 18 (22) :6439-6447
[17]   Proteasome inhibitors and immunosuppressive drugs promote the cleavage of eIF4GI and eIF4GII by caspase-8-independent mechanisms in Jurkat T cell lines [J].
Morley, SJ ;
Pain, VM .
FEBS LETTERS, 2001, 503 (2-3) :206-212
[18]   Reporter gene technology: The future looks bright [J].
Naylor, LH .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (05) :749-757
[19]  
NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239
[20]  
NGUYEN VT, 1989, J BIOL CHEM, V264, P10487